Genetic variations associated with cisplatin-induced ototoxicity identified
the ONA take:
The anti-cancer drug cisplatin is widely administered to treat brain cancer and other tumors, but some individuals treated with cisplatin experience severe hearing loss, among other side effects.
But the effect of patients varies widely. The reasons why some patients were affected has not been fully understood, but a group of investigators based at St. Jude Children's Research Hospital feel the cause of rooted in genetic variations.
The research team examined DNA from 238 patients with brain tumors and took into account some 1.7 million common genetic variations, looking for a link to the cisplatin-related hearing loss. This was the first time a possible genetic cause of this side effect had been investigated.
The result: genetic variations in a gene called ACYP2 were linked to as much as a four-fold increase of risk for hearing loss. This association was verified in a separate group of 68 patients after other risk factors, such as radiation treatment or age, were eliminated. Individuals with at least one copy of the ACYP2 variant experienced hearing loss, establishing a link to that genetic variation, but additional individuals also experienced hearing loss so the researchers feel other, not-yet-identified genetic variations are also at play.
This research could be the first step in identified patients receiving cisplatin that are at high risk of hearing loss. Additional research into why the ACYP2 variations actually trigger the hearing is needed.
The anti-cancer drug cisplatin is widely administered to treat brain cancer and other tumors.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- A Call for More Tailored Cancer Education Programs to Improve Screening
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|